Literature DB >> 25180622

Current therapeutic agents and treatment paradigms for the management of rheumatoid arthritis.

Allan Gibofsky1.   

Abstract

Effective management of rheumatoid arthritis (RA) is based on early treatment with pharmacological agents that are appropriate for the degree of disease activity and the presence or absence of indicators of poor prognosis. The 2012 American College of Rheumatology (ACR) treatment recommendations provide clear guidance for pharmacologic management of patients with RA. Although the optimal use of biologic and non-biologic disease-modifying drugs has transformed the treatment of RA to the extent that remission is a reasonable expectation, choice of a particular agent for use in a specific clinical situation remains unclear. Recently, Cochrane reviews as well as a Comparative Effectiveness Review by the Agency for Healthcare Research and Quality have examined the safety and efficacy of these drugs, with a particular emphasis on biologics. The conclusions of these reviews will be examined in the context of the ACR treatment recommendations.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25180622

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  6 in total

1.  Prevalence of comorbidities and their associations with health-related quality of life and healthcare expenditures in patients with rheumatoid arthritis.

Authors:  JaeJin An; Eric Nyarko; Mohammad Adam Hamad
Journal:  Clin Rheumatol       Date:  2019-05-27       Impact factor: 2.980

2.  Peptide-targeted liposomal delivery of dexamethasone for arthritis therapy.

Authors:  Rakeshchandra R Meka; Shivaprasad H Venkatesha; Bodhraj Acharya; Kamal D Moudgil
Journal:  Nanomedicine (Lond)       Date:  2019-04-02       Impact factor: 5.307

3.  Peptide-directed liposomal delivery improves the therapeutic index of an immunomodulatory cytokine in controlling autoimmune arthritis.

Authors:  Rakeshchandra R Meka; Shivaprasad H Venkatesha; Kamal D Moudgil
Journal:  J Control Release       Date:  2018-08-04       Impact factor: 9.776

4.  Anti-inflammatory, anti-rheumatic and analgesic activities of 2-(5-mercapto-1,3,4-oxadiazol-2-yl)-N-propylbenzenesulphonamide (MOPBS) in rodents.

Authors:  Hina Rasheed; Ruqayya Afridi; Ashraf Ullah Khan; Muhammad Zia Ullah; Sidra Khalid; Ayesha Atiq; Humaira Kashif; Muhammad Naeem Ahmed; Yeong Shik Kim; Salman Khan
Journal:  Inflammopharmacology       Date:  2018-02-22       Impact factor: 4.473

5.  Analgesic and Anti-Inflammatory Activities of Sophocarpine from Sophora viciifolia Hance.

Authors:  F L Wang; H Wang; J H Wang; D X Wang; Y Gao; B Yang; H J Yang; Y B Ji; G S Xin
Journal:  Biomed Res Int       Date:  2021-11-08       Impact factor: 3.411

6.  Changes in Opioid Utilization Following Tumor Necrosis Factor Inhibitor Initiation in Patients with Rheumatoid Arthritis.

Authors:  Siyeon Park; Tham T Le; Julia F Slejko; Ester Villalonga-Olives; Eberechukwu Onukwugha
Journal:  Rheumatol Ther       Date:  2019-10-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.